Very early researchNot Yet RecruitingNCT07213882
What this trial is testing
A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)
Who this might be right for
Cutaneous T Cell Lymphoma (CTCL)Mycosis FungoidesSezary Syndrome
Assistance Publique - Hôpitaux de Paris 30